# Crossject SA

Canonical: https://abierto.us/vendors/crossject-sa-nlxzhcl3nll3

- UEI: NLXZHCL3NLL3
- CAGE: FBEF0
- Location: Dijon, FRA
- Awards in window: 1 (2 transactions), $11,291,005 obligated, May 31, 2024 to September 16, 2025

## Awarding agencies

- Office of Assistant Secretary for Preparedness and Response: 1 awards, $11,291,005

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $11,291,005

## Competition

- Full and Open Competition: 1 awards

## Largest awards

- 75A50122C00031 (definitive contract): $11,291,005, Barda - Aspr / Daappo / Barda DCMA. Advanced Research and Development and Delivery of Adult and Pediatric Midazolam Autoinjectors That Have Received Emergency Use Authorization (Eua) or FDA Approval for the Treatment of Status Epilepticus Seizures in Adult and Pediatric Populations (2+. https://www.usaspending.gov/award/CONT_AWD_75A50122C00031_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/crossject-sa-nlxzhcl3nll3.